New Delhi: India has initiated anti-dumping probes against imports of Glycine, used as a flavour enhancer, and a pharmaceutical ingredient from China, following a complaint filed by a domestic manufacturer.
The application was filed by Avid Organics before the Commerce Ministry's Directorate General of Trade Remedies (DGTR) to initiate the probe.
The applicant has alleged that the dumped imports from China are causing material injury to it. It has requested the imposition of an anti-dumping duty on the imports, according to a DGTR notification.
For the probe, the directorate will consider the data between 2022-25.
"The authority hereby initiates an anti-dumping investigation to determine the existence, degree, and effect of the dumping," it said on Tuesday.
If it is established that the dumping has caused material injury to domestic players, the DGTR would recommend the imposition of duties on the imports.
The finance ministry takes the final decision to impose these duties.
US-China trade tensions and China's significant industrial overcapacity pose a major risk of cheap Chinese goods being dumped in India.
In recent years, India has initiated multiple such probes against dumped imports of certain goods from China.
Anti-dumping probes are conducted by countries to determine if domestic industries have been hurt because of a surge in cheap imports.
As a countermeasure, they impose these duties under the multilateral regime of the Geneva-based World Trade Organisation (WTO). The duty is aimed at ensuring fair trading practices and creating a level playing field for domestic producers vis-à-vis foreign producers and exporters.
India and China are both members of the WTO.
India has already imposed anti-dumping duties on several products to tackle cheap imports from various countries, including China.
India's exports to China rose 36.66 per cent to $19.47 billion during the last fiscal year, while imports increased 16 per cent to $131.63 billion. The trade deficit swelled to an all-time high of $112.6 billion in 2025-26 as against $99.2 billion in 2024-25.